Alimentary Pharmacology & Therapeutics

The gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans
pp. 1-9(9)
Authors: Hawkey, C. J.; Jackson, L.; Harper, S. E.; Simon, T. J.; Mortensen, E.; Lines, C. R.

Effect of Lactobacillus ingestion on the gastrointestinal mucosal barrier alterations induced by indometacin in humans
pp. 11-17(7)
Authors: Gotteland, M.; Cruchet, S.; Verbeke, S.

Randomized trial of low-dose misoprostol and naproxen vs. nabumetone to prevent recurrent upper gastrointestinal haemorrhage in users of non-steroidal anti-inflammatory drugs
pp. 19-24(6)
Authors: Chan, F. K. L.; Sung, J. J. Y.; Ching, J. Y. L.; Wu, J. C. Y.; Lee, Y. T.; Leung, W. K.; Hui, Y.; Chan, L. Y.; Lai, A. C. W.; Chung, S. C. S.

Up-regulation of cyclooxygenase-1 and -2 in human gastric ulcer
pp. 25-34(10)
Authors: To, K. F.; Chan, F. K. L.; Cheng, A. S. L.; Lee, T. L.; Ng, Y. P.; Sung, J. J. Y.

Efficacy of parenteral methotrexate in refractory Crohn's disease
pp. 35-44(10)
Authors: Chong, R. Y.; Hanauer, S. B.; Cohen, R. D.

Effect of food on the pharmacokinetics of budesonide controlled ileal release capsules in patients with active Crohn's disease
pp. 45-51(7)
Authors: Lundin, P.; Naber, T.; Nilsson, M.; Edsbäcker, S.

Once versus divided daily dosing with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters
pp. 53-62(10)
Authors: Hussain, F. N.; Ajjan, R. A.; Kapur, K.; Moustafa, M.; Riley, S. A.

Helicobacter pylori screening for individuals requiring chronic NSAID therapy: a decision analysis
pp. 63-71(9)
Authors: Scheiman, J. M.; Bandekar, R. R.; Chernew, M. E.; Fendrick, A. M.

Accuracy of the stool antigen test in the diagnosis of Helicobacter pylori infection before treatment and in patients on omeprazole therapy
pp. 73-79(7)
Authors: Manes, G.; Balzano, A.; Iaquinto, G.; Ricci, C.; Piccirillo, M. M.; Giardullo, N.; Todisco, A.; Lioniello, M.; Vaira, D.

A multicentre study on eradication of Helicobacter pylori using four 1-week triple therapies in China
pp. 81-86(6)
Authors: Xiao, S.-D.; Liu, W.-Z.; Hu, P.-J.; Ouyang, Q.; Wang, J.-L.; Zhou, L.-Y.; Cheng, N.-N.

Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole
pp. 87-103(17)
Authors: Hirschowitz, B. I.; Haber, M. M.

Duration of effect of lansoprazole on gastric pH and acid secretion in normal male volunteers
pp. 105-113(9)
Authors: Bell, N.; Karol, M. D.; Sachs, G.; Greski-Rose, P.; Jennings, D. E.; Hunt, R. H.

Oesophageal transit, disintegration and gastric emptying of a film-coated risedronate placebo tablet in gastro-oesophageal reflux disease and normal control subjects
pp. 115-121(7)
Authors: Perkins, A. C.; Wilson, C. G.; Frier, M.; Blackshaw, P. E.; Juan, D.; Dansereau, R. J.; Hathaway, S.; Li, Z.; Long, P.; Spiller, R. C.

Ursodeoxycholic acid alone or with chenodeoxycholic acid for dissolution of cholesterol gallstones: a randomized multicentre trial
pp. 123-128(6)
Authors: Petroni, M. L.; Jazrawi, R. P.; Pazzi, P.; Lanzini, A.; Zuin, M.; Pigozzi, M. G.; Fracchia, M.; Galatola, G.; Alvisi, V.; Heaton, K. W.; Podda, M.; Northfield, T. C.

Combination therapy with ribavirin and alpha interferon for the treatment of chronic hepatitis C refractory to interferon
pp. 129-135(7)
Authors: Cozzolongo, R.; Cuppone, R.; Giannuzzi, V.; Amati, L.; Caradonna, L.; Tamborrino, V.; Jirillo, E.; Manghisi, O. G.

Oral hypoglycaemic drugs and gastrointestinal symptoms in diabetes mellitus
pp. 137-142(6)
Authors: Bytzer, P.; Talley, N. J.; Jones, M. P.; Horowitz, M.

Rifabutin-based Helicobacter pylori eradication `rescue therapy'
pp. 143-143(1)
Authors: Canducci, F.; Ojetti, V.; Pola, P.; Gasbarrini, G.; Gasbarrini, A.